CY1115374T1 - Αναστολεiς μετ για ενiσχυση αποτελεσματικoτητας ραδιοθεραπειας - Google Patents
Αναστολεiς μετ για ενiσχυση αποτελεσματικoτητας ραδιοθεραπειαςInfo
- Publication number
- CY1115374T1 CY1115374T1 CY20141100561T CY141100561T CY1115374T1 CY 1115374 T1 CY1115374 T1 CY 1115374T1 CY 20141100561 T CY20141100561 T CY 20141100561T CY 141100561 T CY141100561 T CY 141100561T CY 1115374 T1 CY1115374 T1 CY 1115374T1
- Authority
- CY
- Cyprus
- Prior art keywords
- met
- suspension
- enhance radiotherapy
- cdrs
- radiotherapy efficacy
- Prior art date
Links
- 238000001959 radiotherapy Methods 0.000 title abstract 2
- 239000000725 suspension Substances 0.000 title 1
- 239000003112 inhibitor Substances 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP11158861.2A EP2500036B1 (en) | 2011-03-18 | 2011-03-18 | MET inhibitors for enhancing radiotherapy efficacy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1115374T1 true CY1115374T1 (el) | 2017-01-04 |
Family
ID=44260211
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141100561T CY1115374T1 (el) | 2011-03-18 | 2014-07-24 | Αναστολεiς μετ για ενiσχυση αποτελεσματικoτητας ραδιοθεραπειας |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20120237524A1 (enExample) |
| EP (1) | EP2500036B1 (enExample) |
| JP (1) | JP5671487B2 (enExample) |
| KR (1) | KR101540838B1 (enExample) |
| CN (1) | CN102688491A (enExample) |
| AU (1) | AU2012201303B2 (enExample) |
| BR (1) | BR102012006063B1 (enExample) |
| CA (1) | CA2769991C (enExample) |
| CY (1) | CY1115374T1 (enExample) |
| DK (1) | DK2500036T3 (enExample) |
| EA (1) | EA028590B1 (enExample) |
| ES (1) | ES2489475T3 (enExample) |
| HR (1) | HRP20140729T1 (enExample) |
| IL (1) | IL218293A (enExample) |
| MX (1) | MX2012003084A (enExample) |
| PL (1) | PL2500036T3 (enExample) |
| PT (1) | PT2500036E (enExample) |
| RS (1) | RS53468B (enExample) |
| SG (1) | SG184637A1 (enExample) |
| SI (1) | SI2500036T1 (enExample) |
| SM (1) | SMT201400106B (enExample) |
| ZA (1) | ZA201201992B (enExample) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9168300B2 (en) | 2013-03-14 | 2015-10-27 | Oncomed Pharmaceuticals, Inc. | MET-binding agents and uses thereof |
| TWI782930B (zh) | 2016-11-16 | 2022-11-11 | 美商再生元醫藥公司 | 抗ｍｅｔ抗體，結合ｍｅｔ之雙特異性抗原結合分子及其使用方法 |
| IT201800009282A1 (it) * | 2018-10-09 | 2020-04-09 | Metis Prec Medicine Sb Srl | Nuovo agente terapeutico per il trattamento di un tumore e/o metastasi |
| CN110320365B (zh) * | 2019-07-06 | 2022-07-22 | 湖南莱拓福生物科技有限公司 | NF-κB RelA/p65蛋白位点特异性磷酸化诊断试剂盒 |
| US11896682B2 (en) | 2019-09-16 | 2024-02-13 | Regeneron Pharmaceuticals, Inc. | Radiolabeled MET binding proteins for immuno-PET imaging and methods of use thereof |
| WO2024206858A1 (en) | 2023-03-30 | 2024-10-03 | Revolution Medicines, Inc. | Compositions for inducing ras gtp hydrolysis and uses thereof |
| WO2024229406A1 (en) | 2023-05-04 | 2024-11-07 | Revolution Medicines, Inc. | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| TW202530228A (zh) | 2023-10-12 | 2025-08-01 | 美商銳新醫藥公司 | Ｒａｓ抑制劑 |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI310684B (en) * | 2000-03-27 | 2009-06-11 | Bristol Myers Squibb Co | Synergistic pharmaceutical kits for treating cancer |
| BRPI0407446A (pt) * | 2003-02-13 | 2006-01-31 | Pharmacia Corp | Anticorpos para c-met para o tratamento de cânceres |
| EP1648998B1 (en) * | 2003-07-18 | 2014-10-01 | Amgen Inc. | Specific binding agents to hepatocyte growth factor |
| HN2004000285A (es) * | 2003-08-04 | 2006-04-27 | Pfizer Prod Inc | ANTICUERPOS DIRIGIDOS A c-MET |
| EP1981981B1 (en) * | 2006-02-06 | 2011-06-29 | Metheresis Translational Research SA | Anti-met monoclonal antibody, fragments and vectors thereof, for the treatment of tumors and corresponding products |
| EP2019116A1 (en) * | 2007-07-26 | 2009-01-28 | Helmholtz-Zentrum für Infektionsforschung GmbH | Inhibitor of the met-receptor and its use |
-
2011
- 2011-03-18 DK DK11158861.2T patent/DK2500036T3/da active
- 2011-03-18 EP EP11158861.2A patent/EP2500036B1/en active Active
- 2011-03-18 SI SI201130217T patent/SI2500036T1/sl unknown
- 2011-03-18 PL PL11158861T patent/PL2500036T3/pl unknown
- 2011-03-18 PT PT111588612T patent/PT2500036E/pt unknown
- 2011-03-18 RS RS20140404A patent/RS53468B/sr unknown
- 2011-03-18 ES ES11158861.2T patent/ES2489475T3/es active Active
-
2012
- 2012-02-22 SG SG2012012514A patent/SG184637A1/en unknown
- 2012-02-23 IL IL218293A patent/IL218293A/en active IP Right Grant
- 2012-02-24 JP JP2012039193A patent/JP5671487B2/ja active Active
- 2012-03-01 CA CA2769991A patent/CA2769991C/en active Active
- 2012-03-02 AU AU2012201303A patent/AU2012201303B2/en active Active
- 2012-03-13 MX MX2012003084A patent/MX2012003084A/es active IP Right Grant
- 2012-03-13 KR KR1020120025311A patent/KR101540838B1/ko active Active
- 2012-03-16 ZA ZA2012/01992A patent/ZA201201992B/en unknown
- 2012-03-16 EA EA201200329A patent/EA028590B1/ru not_active IP Right Cessation
- 2012-03-16 CN CN2012100803665A patent/CN102688491A/zh active Pending
- 2012-03-16 BR BR102012006063-9A patent/BR102012006063B1/pt active IP Right Grant
- 2012-03-19 US US13/423,830 patent/US20120237524A1/en not_active Abandoned
-
2014
- 2014-07-24 CY CY20141100561T patent/CY1115374T1/el unknown
- 2014-07-29 HR HRP20140729AT patent/HRP20140729T1/hr unknown
- 2014-07-31 SM SM201400106T patent/SMT201400106B/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2769991C (en) | 2018-05-15 |
| RS53468B (sr) | 2014-12-31 |
| CA2769991A1 (en) | 2012-09-18 |
| AU2012201303B2 (en) | 2013-11-07 |
| AU2012201303A1 (en) | 2012-10-04 |
| KR20120106582A (ko) | 2012-09-26 |
| SG184637A1 (en) | 2012-10-30 |
| EA201200329A3 (ru) | 2013-01-30 |
| ES2489475T3 (es) | 2014-09-02 |
| PT2500036E (pt) | 2014-08-25 |
| IL218293A (en) | 2016-06-30 |
| HRP20140729T1 (hr) | 2014-08-29 |
| JP2012196206A (ja) | 2012-10-18 |
| PL2500036T3 (pl) | 2014-10-31 |
| EA201200329A2 (ru) | 2012-09-28 |
| IL218293A0 (en) | 2012-07-31 |
| BR102012006063A2 (pt) | 2021-11-16 |
| SMT201400106B (it) | 2014-11-10 |
| KR101540838B1 (ko) | 2015-08-06 |
| US20120237524A1 (en) | 2012-09-20 |
| HK1174539A1 (en) | 2013-06-14 |
| JP5671487B2 (ja) | 2015-02-18 |
| CN102688491A (zh) | 2012-09-26 |
| EP2500036B1 (en) | 2014-05-07 |
| MX2012003084A (es) | 2012-09-17 |
| DK2500036T3 (da) | 2014-08-04 |
| BR102012006063A8 (pt) | 2022-11-08 |
| SI2500036T1 (sl) | 2014-09-30 |
| EP2500036A1 (en) | 2012-09-19 |
| EA028590B1 (ru) | 2017-12-29 |
| BR102012006063B1 (pt) | 2023-03-07 |
| ZA201201992B (en) | 2015-05-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1115374T1 (el) | Αναστολεiς μετ για ενiσχυση αποτελεσματικoτητας ραδιοθεραπειας | |
| CY1121148T1 (el) | Παραγοντες συνδεσης vegf/dll4 και χρησεις αυτων | |
| CY1122707T1 (el) | Ετεροκυκλικοι αναστολεις γλουταμινασης | |
| EA201492137A1 (ru) | Антитела к cd33 и их применение в лечении рака | |
| MX2020010639A (es) | Anticuerpos humanizados a liv-1 y uso de los mismos para tratar cancer. | |
| HRP20182202T1 (hr) | Upotreba t stanica modificiranih himernim receptorom za antigen za liječenje raka | |
| CY1120359T1 (el) | Σταθερες φαρμακοτεχνικες μορφες αντισωματων εναντι ανθρωπινου υποδοχεα pd-1 προγραμματισμενου θανατου και σχετικες θεραπειες | |
| PH12016501384A1 (en) | Human antibodies to pd-l1 | |
| TR201905909T4 (tr) | Kanser tedavisi için anti-4-1bb antikorlarının ve adcc indükleyici antikorların kombinasyonları. | |
| CY1119445T1 (el) | Αντισωματα εναντι του ανθρωπινου gdf8 | |
| MX370818B (es) | Anticuerpos anti-b7-h1 para tratar tumores. | |
| EA201690167A1 (ru) | Гуманизованные или химерные антитела к cd3 | |
| MX2016012094A (es) | Composiciones de anticuerpos para tratamiento tumoral. | |
| DK2766040T3 (da) | Pertuzumab, trastuzumab, docetaxel og carboplatin til behandling af brystkræft i et tidligt stadie | |
| EA201890162A1 (ru) | Антитела к cd40 с повышенной агонистической активностью | |
| MX360141B (es) | Anticuerpos contra integrina alfavhbeta6 y uso de los mismos para tratar cancer. | |
| NZ626610A (en) | Antibodies that bind csf1r | |
| EA201290727A1 (ru) | Пирролбензодиазепины и их конъюгаты | |
| NZ611785A (en) | Anti-notch1 antibodies | |
| EA201201474A1 (ru) | Способы лечения рака молочной железы | |
| BR112014024017A8 (pt) | Métodos de tratamento de um tipo de câncer, de tratamento do carcinoma, para selecionar uma terapia e para quantificação e inibidor de her3 | |
| EA201490944A1 (ru) | Двойной ингибитор met и vegf для лечения рака | |
| EA201690599A1 (ru) | Конъюгированные антитела против ly75 для лечения рака | |
| EA201300610A1 (ru) | Хиназолинкарбоксамидазетидины | |
| EA201400339A1 (ru) | Новые имидазоламины в качестве модуляторов киназной активности |